Erin Milner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erin Milner has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Chi K. Nguyen
Department of Chemistry and Life Science, United States Military Academy, 753 Cullum Rd, West Point, New York 10996, United States
2 shared publications - Matthew Armstrong
Department of Chemistry and Life Science, Chemical Engineering Program, United States Military Academy, West Point, NY, United States
2 shared publications Melinda Gleaton
Department of Pathology, Eisenhower Army Medical Center, Fort Gordon, USA
2 shared publicationsMichael Ainsworth
Department of Chemistry and Life Science, United States Military Academy, West Point, USA
2 shared publications- Trevor Corrigan
Department of Bioengineering, University of Washington, 3720 15th Ave NE, Seattle, Washington 98195, USA
2 shared publications Andre Pincot
Department of Chemistry and Life Science, United States Military Academy , West Point, New York 10996, USA
1 shared publication
Latest Publications
- 31 October 2022
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 23 (1) , 59-66
A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations
Background Apixaban is a substrate for p-glycoprotein and is extensively metabolized by cytochrome P450 (CYP) 3A4. There are minimal published data regarding the effect of amiodarone and diltiazem on apixaban serum concentrations. Objective The aim of this study was to determine the degree of elevation of apixaban concentrations resulting from amiodarone or diltiazem. Methods This was a matched cohort study approved by the Institutional Review Board. Patients receiving apixaban 5 mg twice daily with concomitant diltiazem or amiodarone were enrolled. Control groups were enrolled via matching characteristics of sex, age, weight, creatinine clearance, and statin therapy. Exclusions were an inappropriate dosage of apixaban or concomitant dronedarone, verapamil, ranolazine, naproxen, or both amiodarone and diltiazem. Blood samples were collected 3–4 h after and 0.5–2 h before an apixaban dose, corresponding to peak and trough concentrations, respectively. Results were compared using a t test. Results Thirty patients were enrolled in each of the four groups. The mean peak apixaban concentration was 239 ± 82 ng/mL in the amiodarone group and 208 ± 66 ng/mL in the corresponding control group (p = 0.068). Trough concentrations were 142 ± 71 ng/mL and 117 ± 41 ng/mL, respectively (p = 0.055). The mean peak apixaban concentration was 243 ± 99 ng/mL in the diltiazem group and 213 ± 82 ng/mL in the control group (p = 0.11). Trough concentrations were 130 ± 65 ng/mL and 108 ± 54 ng/mL, respectively (p = 0.09). Conclusion Coadministration of amiodarone and diltiazem resulted in a trend toward increased apixaban concentrations. The extent of elevation suggests that empiric dose changes are not necessary; however, individual patients may benefit from monitoring and dose adjustment.
- 31 October 2022
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 23 (1) , 59-66
A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations
Background Apixaban is a substrate for p-glycoprotein and is extensively metabolized by cytochrome P450 (CYP) 3A4. There are minimal published data regarding the effect of amiodarone and diltiazem on apixaban serum concentrations. Objective The aim of this study was to determine the degree of elevation of apixaban concentrations resulting from amiodarone or diltiazem. Methods This was a matched cohort study approved by the Institutional Review Board. Patients receiving apixaban 5 mg twice daily with concomitant diltiazem or amiodarone were enrolled. Control groups were enrolled via matching characteristics of sex, age, weight, creatinine clearance, and statin therapy. Exclusions were an inappropriate dosage of apixaban or concomitant dronedarone, verapamil, ranolazine, naproxen, or both amiodarone and diltiazem. Blood samples were collected 3–4 h after and 0.5–2 h before an apixaban dose, corresponding to peak and trough concentrations, respectively. Results were compared using a t test. Results Thirty patients were enrolled in each of the four groups. The mean peak apixaban concentration was 239 ± 82 ng/mL in the amiodarone group and 208 ± 66 ng/mL in the corresponding control group (p = 0.068). Trough concentrations were 142 ± 71 ng/mL and 117 ± 41 ng/mL, respectively (p = 0.055). The mean peak apixaban concentration was 243 ± 99 ng/mL in the diltiazem group and 213 ± 82 ng/mL in the control group (p = 0.11). Trough concentrations were 130 ± 65 ng/mL and 108 ± 54 ng/mL, respectively (p = 0.09). Conclusion Coadministration of amiodarone and diltiazem resulted in a trend toward increased apixaban concentrations. The extent of elevation suggests that empiric dose changes are not necessary; however, individual patients may benefit from monitoring and dose adjustment.
- Open Access
- 15 January 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (5) , 668-675
Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
What is known and objectives Although the apixaban Food and Drug Administration (FDA) package insert recommends dose reduction in patients administered dual strong inhibitors of p-glycoprotein (P-gp) and cytochrome P-450 (CYP) 3A4, there are limited published data regarding potential drug-drug interactions between apixaban (Eliquis) and common p-glycoprotein (P-gp) and CYP3A4 inhibitors co-administered with statins. The aim of this study was to investigate the degree of elevation relative to apixaban serum peak and trough concentration after the co-administration of amiodarone, diltiazem and statins (atorvastatin, rosuvastatin and simvastatin). Methods Patients prescribed apixaban 5mg twice daily for at least one week were identified from the anticoagulation clinic database and contacted for potential enrolment. A total of 117 volunteers were enrolled with eight excluded due to discontinued use, resulting in 109 volunteers (44 females and 65 males delineated into age groups 40–64 and ≥65 years old) completing the observational study. Fifty-five volunteers were administered apixaban without the P-gp inhibitors amiodarone or diltiazem, with or without statins (atorvastatin, rosuvastatin and simvastatin). Fifty-four volunteers were administered apixaban with either amiodarone or diltiazem, with or without statins (atorvastatin, rosuvastatin or simvastatin). Peak and trough concentrations were assessed for each patient utilizing an apixaban anti-Xa assay. Results Of the combinations studied, the mean apixaban trough concentration upon co-administration of amiodarone without a statin was elevated compared to apixaban alone (experimental 156.83 +/− 79.59 ng/ml vs. control 104.09 +/− 44.56 ng/ml; p = 0.04). The co-administration of diltiazem and rosuvastatin, and the administration of amiodarone without a statin led to greater than 1.5-fold increase in apixaban concentrations (peak experimental 315.19 +/− 157.53 ng/ml vs control 207.6 +/− 83.38 ng/ml; p = 0.08 and trough experimental 182.03 +/− 95.93 ng/ml vs control 112.32 +/− 37.78 ng/ml; p = 0.17) suggesting the need to assess dose adjustment for patients per the FDA package insert. In addition, the aggregated mean peak (p = 0.0056) and trough (p = 0.0089) elevation of CYP3A4 experimental groups (atorvastatin and simvastatin) co-administered apixaban and diltiazem were statistically significant compared with the aggregated non-CYP3A4 control groups (no statin and rosuvastatin). What is new and conclusion Herein, we report novel data regarding peak and trough apixaban concentrations after concomitant administration of P-gp and CYP3A4 inhibitors (amiodarone or diltiazem) co-administered with statins (atorvastatin, rosuvastatin or simvastatin). Providers should consider utilizing the apixaban anti-Xa assay or comparative heparin anti-Xa assay to determine if patients require dose reduction to decrease adverse events in high-risk patients prescribed apixaban and concomitant p-glycoprotein and CYP3A4 inhibitors amiodarone or diltiazem with and without a CYP3A4 or non-3A4 statin.
- 15 January 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (5) , 668-675
Open AccessAssessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
What is known and objectives Although the apixaban Food and Drug Administration (FDA) package insert recommends dose reduction in patients administered dual strong inhibitors of p-glycoprotein (P-gp) and cytochrome P-450 (CYP) 3A4, there are limited published data regarding potential drug-drug interactions between apixaban (Eliquis) and common p-glycoprotein (P-gp) and CYP3A4 inhibitors co-administered with statins. The aim of this study was to investigate the degree of elevation relative to apixaban serum peak and trough concentration after the co-administration of amiodarone, diltiazem and statins (atorvastatin, rosuvastatin and simvastatin). Methods Patients prescribed apixaban 5mg twice daily for at least one week were identified from the anticoagulation clinic database and contacted for potential enrolment. A total of 117 volunteers were enrolled with eight excluded due to discontinued use, resulting in 109 volunteers (44 females and 65 males delineated into age groups 40–64 and ≥65 years old) completing the observational study. Fifty-five volunteers were administered apixaban without the P-gp inhibitors amiodarone or diltiazem, with or without statins (atorvastatin, rosuvastatin and simvastatin). Fifty-four volunteers were administered apixaban with either amiodarone or diltiazem, with or without statins (atorvastatin, rosuvastatin or simvastatin). Peak and trough concentrations were assessed for each patient utilizing an apixaban anti-Xa assay. Results Of the combinations studied, the mean apixaban trough concentration upon co-administration of amiodarone without a statin was elevated compared to apixaban alone (experimental 156.83 +/− 79.59 ng/ml vs. control 104.09 +/− 44.56 ng/ml; p = 0.04). The co-administration of diltiazem and rosuvastatin, and the administration of amiodarone without a statin led to greater than 1.5-fold increase in apixaban concentrations (peak experimental 315.19 +/− 157.53 ng/ml vs control 207.6 +/− 83.38 ng/ml; p = 0.08 and trough experimental 182.03 +/− 95.93 ng/ml vs control 112.32 +/− 37.78 ng/ml; p = 0.17) suggesting the need to assess dose adjustment for patients per the FDA package insert. In addition, the aggregated mean peak (p = 0.0056) and trough (p = 0.0089) elevation of CYP3A4 experimental groups (atorvastatin and simvastatin) co-administered apixaban and diltiazem were statistically significant compared with the aggregated non-CYP3A4 control groups (no statin and rosuvastatin). What is new and conclusion Herein, we report novel data regarding peak and trough apixaban concentrations after concomitant administration of P-gp and CYP3A4 inhibitors (amiodarone or diltiazem) co-administered with statins (atorvastatin, rosuvastatin or simvastatin). Providers should consider utilizing the apixaban anti-Xa assay or comparative heparin anti-Xa assay to determine if patients require dose reduction to decrease adverse events in high-risk patients prescribed apixaban and concomitant p-glycoprotein and CYP3A4 inhibitors amiodarone or diltiazem with and without a CYP3A4 or non-3A4 statin.
- Open Access
- 1 November 2021
- Published by AIP Publishing in AIP Advances
- Vol. 11 (11) , 115226
Probing microstructural differences that manifest in human blood after taking aspirin using thixo-elasto-visco-plastic modeling and series of physical processes
Although prophylactic use of low dosage acetylsalicylic acid (aspirin) to inhibit the effects of platelet aggregation is common, a few, if any, rheological studies validating the change in the physical and mechanical properties of human blood post-aspirin administration have been reported. Recent work modeling the rheological behavior of thixo-elasto-visco-plastic materials, such as human blood, indicates that they have all the hallmark features of a complex material, including shear-thinning, viscoelasticity, yield stress, and thixotropy. Using human blood rheological data collected on a Discovery Hybrid Rheometer, before and after a 14-day protocol of once daily 81 mg aspirin tablet, we compare the mechanical properties with the recently published enhanced thixotropic modified Horner–Armstrong–Wagner–Beris thixo-elasto-visco-plastic model and sequence of physical processes. We do so to highlight the subtle shift in mechanical properties in terms of the “liquid-like” and “solid-like” nature of blood. We will show both before and after parametric analysis, profile, and comparison, as well as the before and after aspirin elastic and viscous properties of the human blood.
- 1 November 2021
- Published by AIP Publishing in AIP Advances
- Vol. 11 (11) , 115226
Open AccessProbing microstructural differences that manifest in human blood after taking aspirin using thixo-elasto-visco-plastic modeling and series of physical processes
Although prophylactic use of low dosage acetylsalicylic acid (aspirin) to inhibit the effects of platelet aggregation is common, a few, if any, rheological studies validating the change in the physical and mechanical properties of human blood post-aspirin administration have been reported. Recent work modeling the rheological behavior of thixo-elasto-visco-plastic materials, such as human blood, indicates that they have all the hallmark features of a complex material, including shear-thinning, viscoelasticity, yield stress, and thixotropy. Using human blood rheological data collected on a Discovery Hybrid Rheometer, before and after a 14-day protocol of once daily 81 mg aspirin tablet, we compare the mechanical properties with the recently published enhanced thixotropic modified Horner–Armstrong–Wagner–Beris thixo-elasto-visco-plastic model and sequence of physical processes. We do so to highlight the subtle shift in mechanical properties in terms of the “liquid-like” and “solid-like” nature of blood. We will show both before and after parametric analysis, profile, and comparison, as well as the before and after aspirin elastic and viscous properties of the human blood.
- 4 August 2021
- Published by SAGE Publications in Biorheology
- Vol. 58 (1-2) , 1-26
Visualizing and exploring nonlinear behavior, timescales, and mechanical signatures of human blood
BACKGROUND: Human blood is a thixo-elasto-visco-plastic (TEVP) material that exhibits unique fluctuations in mechanical properties based on physiology, and shear rate. We demonstrate new visual tools to help visualize and characterize these varied mechanical properties. OBJECTIVE: Our objective is to demonstrate contemporary visual and numerical tools to help visualize and characterize the varied mechanical properties of human blood. METHODS: Using the ARESG2 strain-controlled rheometer with double wall couette geometry and eight human blood donors, with lab test results, elastic and viscous properties are investigated using Series of Physical Processes (SPP) and MITLaos to both analyze and visualize the mechanical signatures of the blood. RESULTS: Variations of mechanical properties are shown via SPP generated Cole-Cole plots and MITLaos analysis. These variations are a function of physiological properties of blood on the day of the blood draw based on hematocrit, fibrinogen, cholesterol, triglycerides, and a host of other proteins and constituents. Each rheological experiment with blood is replicated with an analogous experiments with 0.04 wt% xanthan in glycerol, and water to demonstrate that the mechanical properties of the human blood, and its rheological signatures are unique to human blood. CONCLUSIONS: Human blood is proven to be a TEVP material, as shown on a series of Cole-Cole plots for eight different donors, at two different frequency and strain amplitude combinations. Variations in Cole-Cole plots for each donor are shown. MITLaos average mechanical properties are calculated and shown. Aggregated elastic and viscous projections and a Cole-Cole plot is shown for Donors 1–8, along with 95% confidence interval.
- 4 August 2021
- Published by SAGE Publications in Biorheology
- Vol. 58 (1-2) , 1-26
Visualizing and exploring nonlinear behavior, timescales, and mechanical signatures of human blood
BACKGROUND: Human blood is a thixo-elasto-visco-plastic (TEVP) material that exhibits unique fluctuations in mechanical properties based on physiology, and shear rate. We demonstrate new visual tools to help visualize and characterize these varied mechanical properties. OBJECTIVE: Our objective is to demonstrate contemporary visual and numerical tools to help visualize and characterize the varied mechanical properties of human blood. METHODS: Using the ARESG2 strain-controlled rheometer with double wall couette geometry and eight human blood donors, with lab test results, elastic and viscous properties are investigated using Series of Physical Processes (SPP) and MITLaos to both analyze and visualize the mechanical signatures of the blood. RESULTS: Variations of mechanical properties are shown via SPP generated Cole-Cole plots and MITLaos analysis. These variations are a function of physiological properties of blood on the day of the blood draw based on hematocrit, fibrinogen, cholesterol, triglycerides, and a host of other proteins and constituents. Each rheological experiment with blood is replicated with an analogous experiments with 0.04 wt% xanthan in glycerol, and water to demonstrate that the mechanical properties of the human blood, and its rheological signatures are unique to human blood. CONCLUSIONS: Human blood is proven to be a TEVP material, as shown on a series of Cole-Cole plots for eight different donors, at two different frequency and strain amplitude combinations. Variations in Cole-Cole plots for each donor are shown. MITLaos average mechanical properties are calculated and shown. Aggregated elastic and viscous projections and a Cole-Cole plot is shown for Donors 1–8, along with 95% confidence interval.
- 1 May 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (5) , e02000-16
Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia
Despite the rising rates of resistance to dihydroartemisinin-piperaquine (DP), DP remains a first-line therapy for uncomplicated malaria in many parts of Cambodia. While DP is generally well tolerated as a 3-day DP (3DP) regimen, compressed 2-day DP (2DP) regimens were associated with treatment-limiting cardiac repolarization effects in a recent clinical trial. To better estimate the risks of piperaquine on QT interval prolongation, we pooled data from three randomized clinical trials conducted between 2010 and 2014 in northern Cambodia. A population pharmacokinetic model was developed to compare exposure-response relationships between the 2DP and 3DP regimens while accounting for differences in regimen and sample collection times between studies. A 2-compartment model with first-order absorption and elimination without covariates best fit the data. The linear slope-intercept model predicted a 0.05-ms QT prolongation per ng/ml of piperaquine (5 ms per 100 ng/ml) in this largely male population. Though the plasma half-life was similar in both regimens, peak and total piperaquine exposures were higher in those treated with the 2DP regimen. Furthermore, the correlation between the plasma piperaquine concentration and the QT interval prolongation was stronger in the population receiving the 2DP regimen. Neither the time since the previous meal nor the baseline serum magnesium or potassium levels had additive effects on QT interval prolongation. As electrocardiographic monitoring is often nonexistent in areas where malaria is endemic, 2DP regimens should be avoided and the 3DP regimen should be carefully considered in settings where viable alternative therapies exist. When DP is employed, the risk of cardiotoxicity can be mitigated by combining a 3-day regimen, enforcing a 3-h fast before and after administration, and avoiding the concomitant use of QT interval-prolonging medications. (This study used data from three clinical trials that are registered at ClinicalTrials.gov under identifiers NCT01280162, NCT01624337, and NCT01849640.)
- 1 May 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (5) , e02000-16
Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia
Despite the rising rates of resistance to dihydroartemisinin-piperaquine (DP), DP remains a first-line therapy for uncomplicated malaria in many parts of Cambodia. While DP is generally well tolerated as a 3-day DP (3DP) regimen, compressed 2-day DP (2DP) regimens were associated with treatment-limiting cardiac repolarization effects in a recent clinical trial. To better estimate the risks of piperaquine on QT interval prolongation, we pooled data from three randomized clinical trials conducted between 2010 and 2014 in northern Cambodia. A population pharmacokinetic model was developed to compare exposure-response relationships between the 2DP and 3DP regimens while accounting for differences in regimen and sample collection times between studies. A 2-compartment model with first-order absorption and elimination without covariates best fit the data. The linear slope-intercept model predicted a 0.05-ms QT prolongation per ng/ml of piperaquine (5 ms per 100 ng/ml) in this largely male population. Though the plasma half-life was similar in both regimens, peak and total piperaquine exposures were higher in those treated with the 2DP regimen. Furthermore, the correlation between the plasma piperaquine concentration and the QT interval prolongation was stronger in the population receiving the 2DP regimen. Neither the time since the previous meal nor the baseline serum magnesium or potassium levels had additive effects on QT interval prolongation. As electrocardiographic monitoring is often nonexistent in areas where malaria is endemic, 2DP regimens should be avoided and the 3DP regimen should be carefully considered in settings where viable alternative therapies exist. When DP is employed, the risk of cardiotoxicity can be mitigated by combining a 3-day regimen, enforcing a 3-h fast before and after administration, and avoiding the concomitant use of QT interval-prolonging medications. (This study used data from three clinical trials that are registered at ClinicalTrials.gov under identifiers NCT01280162, NCT01624337, and NCT01849640.)